Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Lancet Oncology Année : 2016

Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Résumé

Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF V600-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated effi cacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-01407426 , version 1 (02-12-2016)

Identifiants

  • HAL Id : inserm-01407426 , version 1

Citer

Paolo A. Ascierto, Grant A Mcarthur, Brigitte Dréno, Victoria A Atkinson, Gabrielle Liszkay, et al.. Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, 2016, 17, pp.1248-1260. ⟨inserm-01407426⟩
71 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More